CN1247755A - Hepatitis treating medicine and its production process - Google Patents
Hepatitis treating medicine and its production process Download PDFInfo
- Publication number
- CN1247755A CN1247755A CN99108167A CN99108167A CN1247755A CN 1247755 A CN1247755 A CN 1247755A CN 99108167 A CN99108167 A CN 99108167A CN 99108167 A CN99108167 A CN 99108167A CN 1247755 A CN1247755 A CN 1247755A
- Authority
- CN
- China
- Prior art keywords
- treatment hepatitis
- hours
- production method
- time
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention produces oral liquid for treating hepatitis by using ant as main material and red sage. Astragalus membranaceus and sealwort as supplementary material and through water and alcohol extraction process to extract the effective components. The preparation of the present invention has the functions of strengthening body's resistance, eliminating evil, nourishing Yin, invigorating kidney, benefiting Qi, nourishing liver, promoting blood circulation and dredging the meridian passage. The pharmacodynamical research proves that the preparation has the effects of protecting liver, reducing transaminase, promoting the regeneration of liver cells, reducing BSP retension and strengthening immunity. The clinical practise shows that the preparation has one total effective rate in treating hepatitis up to 81.82%.
Description
The present invention relates to a kind of medicine for the treatment of hepatitis, particularly a kind of is the pharmaceutical composition that raw material is made with insecticide and vegetable Chinese herbal medicine, the invention still further relates to the method for producing this medicine.
Chronic hepatitis and hepatitis B virus infection are the common frdquently encountered diseases of present worldwide serious harm human health.China is one of district occurred frequently of hepatitis disease, and acute hepatitis is sent out about 1,200,000 people of patient in every year, about 1,200 ten thousand people of chronic hepatitis patient, and hepatitis B virus carriers 1.2 hundred million people, and annual infection rate with 10% increasing progressively annually reach 300,000 people approximately because of hepatopathy death person.Therefore, the new drug development work of treatment hepatitis and removing hepatitis B virus just seems urgent and important especially.
Chronic hepatitis is that hepatitis virus is encroached on hepatic tissue and the immune dysfunction that causes and mostly be low pathological manifestations disease for a long time.Modern immunology studies have shown that hepatitis B patient's liver tissue injury is not HBV duplicates propagation in hepatocyte result, but because immunologic function disorder causes a series of abnormal movements to cause.The infection of hepatitis B virus is pathogenesis basis with carrying many for a long time with the immunologic hypofunction, belongs to the category of Chinese medicine " deficient, syndrome of blood stasis ".The treatment present situation current, that chronic hepatitis and hepatitis B virus are removed, clinical symptomatic treatment and the immunological therapy methods that adopt conventional the liver protecting and ALT lowering more.But in clinical treatment, these two kinds of Therapeutic Method often are difficult to reach the effect that gets both, so the clinical practice effect of each Therapeutic Method is all not satisfactory.So, research and develop and a kind ofly can regulate immunologic function, the medicine of function for protecting liver and reducing enzyme activity can be arranged again, to improve chronic hepatitis and the cure rate of removing hepatitis B virus, have practical value and realistic meaning.
China be eat, the native place of medical ant, the medicinal Han dynasty that starts from the earliest of Formica fusca adopted Formica fusca pulverizing refined honey ball to make JINGANG WAN at that time, was used for the treatment of the muscles and bones weakness.The Li Mingzhen of Ming Dynasty work Compendium of Material Medica has been carried out detailed textual criticism record to habit, toxicity, the flavor of Formica fusca, and with Formica fusca called after " XUANJU "; Put down in writing on the Compendium of Material Medica, " property is sweet flat, physical strength profiting, damp color ... also nontoxic for Formica fusca." many in the world now countries such as Mexico, Philippine, Japan, the U.S., Argentina etc., be senior tonic all with Formica fusca food.In recent years, nourishing of Formica fusca and anti-aging effects are subjected to China medical research worker's attention gradually, and Formica fusca are recorded in " delay aging drug ".
Modern medicine study proves that Formica fusca is a kind of broad-spectrum immunostimulant, is again a kind of safe immunosuppressant, has tangible dual regulation, can suppress the growth of fungus and staphylococcus aureus.Clinical practice ant preparation treatment rheumatic arthritis, rheumatoid arthritis etc. have been obtained certain curative effect.Discovering in recent years, the active component of Formica fusca can obviously increase the thymus and the index and spleen index of animal subject, experimental immune hepatic injury is had significantly protect the liver, effect of reducing enzyme levels.
Purpose of the present invention just is to provide a kind of can regulate immunologic function, has function for protecting liver and reducing enzyme activity again, the treatment hepatitis medicament that cure rate is high.
This medicine production method is provided, and is another goal of the invention of the present invention.
For reaching above-mentioned goal of the invention, the present invention in conjunction with the modern medicine study achievement, filters out a kind of new treatment hepatitis medicament according to the tcm theory of " treating the liver elder generation tonifying the spleen, replenishing the kidney(water)to nourish the liver(wood) ".This medicine is made (parts by weight) by following component:
10 parts of 10 parts of Rhizoma Polygonatis of 20 parts of Radixs Astragali of 20 parts of Radix Salviae Miltiorrhizaes of Formica fusca
The present invention is a monarch drug with the Formica fusca, is equipped with Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Polygonati and makes medicament, has the effect of nourishing the liver and kidney, invigorating the spleen and benefiting QI, promoting blood circulation to remove obstruction in the collateral, is used for the treatment of deficiency of both QI and YIN, deficiency of both the liver and kidney, venation block type chronic hepatitis.
Wherein Formica fusca has the effect of kidney and spleen invigorating, YIN nourishing and YANG strengthening, flourish liver collateral dredging; Rhizoma Polygonati is sweet equals, returns spleen, lung, kidney channel, and the effect of YIN nourishing invigorating the spleen and replenishing QI is arranged; The Radix Salviae Miltiorrhizae bitter in the mouth, be slightly cold, GUIXIN, Liver Channel, stasis-dispelling and pain-killing, promoting blood circulation to remove obstruction in the collateral, focus on nourshing blood and promoting blood circulation; The sweet temperature of the Radix Astragali, return lung, spleen channel, invigorating QI to consolidate the body surface resistance, short temper biochemical with transfer precise and tinyly, transfer temper fortuneization to fill blood more.
Studies confirm that of modern pharmacology, Formica fusca contain the various nutrients of needed by human, as fat, protein, vitamin, aminoacid and trace element, its effective ingredient energy mediator body immunity function is removed virus, repairs hepatocyte, the transaminase lowering activity has antiinflammatory, hepatoprotective effect; The Radix Astragali contains sucrose, glucuronic acid and several aminoacid, has anti-aging effects, can regulate immunologic balance, promote lymphocyte transformation, strengthen the T cell function, suppress the immune disease that autoantibody causes, improve immunologic function, the hepatitis patient due to the pair cell immunologic function reduces can strengthen its cellular immunization, improve liver function, prevent that liver glycogen from reducing; Radix Salviae Miltiorrhizae can improve the microcirculation of each important organ of human body significantly, blood viscosity lowering, reduce erythrocyte aggregation, improve velocity of blood flow, strengthen the opening of blood capillary, suppress, alleviate hepatocellular degeneration, necrosis and inflammatory reaction, strengthen reticuloendothelial system phagocytic function and OA, avoid hepar damnification, protect the liver and promote the liver cell regeneration effect thereby play, suppress fibroplasia in the liver, prevent the generation and the development of liver cirrhosis; Rhizoma Polygonati has raise immunity, suppress lipid peroxidation, improve blood rheology parameter, tangible antagonism hepatocyte injury is arranged and increase the effect of serum albumin, what also have anti-fatty liver and suppress hbs antigen protects the liver function and antibiotic, antivirus action.
Formica fusca of the present invention can be any for food, medicinal Formica fusca ant kind.Yet the present invention discovers in the northern China each province distribution is arranged all, wherein abounds with in the geographic emerv formlcusius in mountain, Lvliang City, Shanxi Province (Formica Sinae Emery) better in effect aspect the treatment hepatitis.
Biochemical teaching and research room of Capital Medical College has carried out assay determination to the composition of emerv formlcusius, analysis result shows, the total lipid content of emerv formlcusius is 77%, protein content is respectively 52.8% and 12.15% in dry ant powder and the 10% dry powder water extract, and is rich in several amino acids and trace element.See the following form its concrete composition.
Aminoacid kind and content (mg/100g) in table 1 emerv formlcusius
| Title | Content in the dry powder | Content in the water extract | Title | Content in the dry powder | Water extract content |
| Asparatate threonine serine glutamic acid proline glycine alanine cystine valine | ??4.7 ??2.0 ??2.2 ??3.3 ??1.7 ??2.4 ??2.0 ??1.7 ??1.7 | ???0.784 ???0.225 ???0.335 ???0.337 ???0.442 ???0.442 ???0.579 ???0.022 ???0.438 | Methionine isoleucine leucine tyrosine phenylalanine histidine lysine ammonia arginine | ????0.1 ????2.9 ????5.4 ????0.5 ????3.2 ????0.4 ????0.7 ????1.0 ????1.0 | ?0.167 ?0.364 ?0.189 ?0.340 ?0.384 ?0.116 ?0.129 ?0?250 ?0.563 |
The kind of trace element and content in table 2 emerv formlcusius
| Title | Content in the dry powder (ppm/g) | Content in the water extract (ppm/mL) | Title | Content in the dry powder (ppm/g) | Content in the water extract (ppm/mL) |
| ?Cd ?Cu ?Mn ?Ni ?Pb ?Sr ?Zn ?Ca ?Mg ?K | ??1.818 ??33.31 ??455.4 ??4.922 ??13.09 ??21.75 ??285.8 ??7061 ??2586 ??10717 | ??0.695 ??0.5171 ??34.85 ??0.0115 ??0.162 ??0.848 ??15.12 ??487 ??105.7 ??751.5 | ??Na ??Fe ??Al ??T ??B ??Mo ??P ??S ??U ??Se | ??5708.3 ??6673 ??6341 ??1120 ??37.56 ??11.52 ??7252 ??257.7 ??12.68 ??27.19 | ??206.5 ??9.622 ??16.63 ??- ??30.04 ??0.2547 ??558.4 ??15.55 ??- ??3.302 |
As seen from the above table, all contain 18 seed amino acids in the emerv formlcusius, comprise the aminoacid of 7 kinds of needed by human.Emerv formlcusius is rich in elements such as Cu, Fe, P, Se, Zn, Mn, and wherein Se, Fe, Cu content are higher than the Guangxi Polyhachis vicina Roger, and the content of Zn, Mn, Se is present 2-3 times of having found high-load trace element food.Numerous studies have shown that, Mn is the activator of black thuja acid cyclase, can quicken the generation of CGMP, promoting lymphocytic division, is again the normal condition that produces of antibody, and Se is one of thymus theca cell composition, also be one of trace element of needed by human, can directly promote cellular immune function.
Any dosage form that above-mentioned prescription of the present invention can be made on the pharmaceutics is used, for example oral liquid.
The production method that the present invention produces oral liquid is: Formica fusca powder is broken into coarse powder, add and to be equivalent to dose 6-10 water doubly, flood 24 hours, reuse is equivalent to the water retting 0.5 hour of half amount of water yield first time, merge leachate twice, filter, filtrate decompression is concentrated into the clear paste that relative density is 1.30-1.35 (55 ℃), puts cold, adding ethanol makes the alcohol amount that contains of medicinal liquid reach 70%, staticly settled 24 hours, and got supernatant, filtering and be concentrated into relative density is the concentrated solution of 1.30-1.35 (55 ℃); Get Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Polygonati three flavor Chinese medicines again, add and be equivalent to dose 6-10 water doubly, decoct twice, 2 hours for the first time, 1.5 hours for the second time, collecting decoction filtered, filtrate decompression is concentrated into the clear paste that relative density is 1.30-1.35 (55 ℃), put coldly, add ethanol and make the alcohol amount of containing of medicinal liquid reach 70%, staticly settled 24 hours, get supernatant, filtering and be concentrated into relative density is the concentrated solution of 1.30-1.35 (55 ℃); Merge two kinds of concentrated solutions, in 1: the ratio thin up of 5-8, cold preservation is 48 hours under 0-4 ℃ of condition, filters, and makes the oral liquid product.Product is the supernatant liquid of rufous, pH value 4-5, and relative density 1.01-1.03, feeble QI perfume (or spice), it is little puckery to distinguish the flavor of, little sour-sweet.
In the above-mentioned production method, because major physiological active component several amino acids (comprising in conjunction with aminoacid and free amino acid) of Formica fusca and trace element promptly can leach by water at normal temperatures, so the present invention determines to adopt the active component in the water seaoning technology extraction Formica fusca, and does not decoct jointly with its excess-three flavor Chinese medicine.
In the water seaoning extraction process of Formica fusca, adopt the extracted twice method, the water yield that in the Formica fusca coarse powder, adds 6,8,10 times for the first time respectively, add the water yield dipping of half for the first time for the second time again, select different dip times, investigate after the extracted twice amino acid content in the extracting solution for the third time, result of the test shows, selecting for the first time dip time more than 24 hours, for the second time under 0.5 hour the condition of dip time, aminoacid in the extracting solution detects negatively for the third time, proves that this condition is can lixiviate complete.If dip time was less than 24 hours for the first time, the detection of the aminoacid in the extracting solution for the third time is positive.
In the extraction process of Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Polygonati three flavor Chinese medicines, three medicines are root and tubers Chinese medicine, therefore adopt the classical method that decocts with water.Select different soak times, decocting time, decoction number of times and amount of water condition respectively, with total solid matters weight in the fried liquid is that performance assessment criteria is screened, the result shows that soak time does not make significant difference to the solids yield, other is when selecting each 6-8 times of water gaging decoction that add, decoct twice, 2 hours for the first time, during 1.5 hours process conditions, the yield of solids was the highest for the second time.
The present invention is after extracting effective ingredient and simmer down to clear paste respectively with above four kinds of compositions, also in clear paste, add ethanol respectively and carry out alcohol precipitation process, its objective is macromolecular compounds such as the protein removed in the extracting solution, phlegmatic temperament, tannin, pectin, natural gum, starch, make final products that clarity preferably be arranged, improve the presentation quality of preparation.
Alcohol precipitation process to Formica fusca clear paste and Radix Salviae Miltiorrhizae etc. three flavor Chinese medicine clear paste is investigated respectively, prove that precipitate with ethanol can be obtained satisfied effect in 24 hours when containing pure measuring when being 70%.If the alcohol amount of containing is too little, precipitate with ethanol is incomplete, and the clarity of medicinal liquid is undesirable, and precipitate is not tight, and is muddy easily even pour out when toppling over supernatant.When the alcohol amount of containing greater than 70% the time, though can shorten the precipitate with ethanol time, meet the requirements of effect in the short period of time, can make the loss of effective components in the medicinal liquid excessive simultaneously, influence drug effect.So final selection contains alcohol amount 70%, clarity was both good, did not lose the effective ingredient in the medicinal liquid again.
The present invention can also make the product of said other various dosage forms on the pharmaceutics, for example can be with the clear paste spray dryer drying and granulating after extracting, and packing is made dissolved granule.
In also above-mentioned dried particles can being incapsulated, make capsule.
Show that through the pharmacodynamic study result preparation of the present invention has significant protective effect for multiple tentative animal liver damage, be embodied as following some:
1, bacillus calmette-guerin vaccine is caused the influence of test mice immunologic liver injury: preparation of the present invention has obvious reduction ALT and the active effect of AST; alleviate liver, the splenomegaly program of test mice; and to the liver cell proliferation of hepatic tissue; steatosis, necrosis; the portal area hypertrophy, the infiltration of little bile duct and proliferation of fibrous tissue and inflammatory cell has significant protective effect.
2, carbon tetrachloride is caused the influence of test rat acute liver damage: preparation of the present invention has tangible effect of reducing enzyme levels, and steatosis, hepatocyte edema, the hepatic necrosis of hepatic tissue had significant protective effect.
3, the influence of the test rat chronic hepatic injury that carbon tetrachloride is caused: preparation of the present invention can make total serum protein, and albumin content obviously increases, and the activity of ALT, AST reduces.Pathological examination, the steatosis of preparation of the present invention, hepatic necrosis, proliferation of fibrous tissue is all slighter.
4, to the influence of rat acute liver damage due to the D-Gal (D-galactosamine hydrochlorate): preparation transaminase lowering of the present invention, bilirubin effect are obvious, and the liver coefficient also has the trend of reverse.Pathological examination, the profit of invading of hepatic necrosis, swelling, portal area inflammatory cell reduces.
Pharmacodynamic study finds that also preparation of the present invention also can promote hepatocellular regeneration, makes mouse liver neonatal liver cell number showed increased, and liver regeneration degree regulating liver-QI coefficient all improves.Preparation of the present invention also has the liver of promotion Excretion, reduces the effect of mice BSP retention.
Result of study for the immunology aspect confirms that preparation of the present invention has following effect:
1, obviously promotes the weightening finish of mouse spleen, thymus;
2, obviously improve the effect that Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell;
3, promote the clearance rate of carbon granules foreign body in the mice blood;
4, promote the generation of mice hemolysin;
5, strengthen the transformation of ConA inducing mouse splenocyte;
6, influence the aspect for mouse DTH (delayed hypersensitivity) model, preparation of the present invention has the inhibitory action of highly significant to DNFB DTH, to the too high DTH reacting recovery of Cy induced mice to normal; Low DTH improves and recovery to the Cy induced mice; Can suppress the formation of mice PFC (splenocyte hemolysis plaque).
Above-mentioned immunology studies show that preparation of the present invention has the function of immunity of obvious raising mouse cell and humoral immunization.
In the acute toxicity test of preparation of the present invention, be limited to administration concentration and volume is limit, be difficult to measure the minimum lethal dose of mice, but after giving the mouse stomach administration with the dosage of 112g/kg (be equivalent to adult's consumption 747 times), observed 7 continuously, do not see toxic reaction.
Long term toxicity test is the result also show, preparation of the present invention is given rat continuous irrigation stomach 180 days for 40 times to use 80 times of dosage greater than the adult, and rat body weight increases, peripheral hemogram, blood biochemical function of liver and spleen index and matched group compare, and P＞0.05 is through histological examination, ten kinds of organs and tissues such as the high dose group rat heart, liver, spleen, lung, kidney, testis and matched group are relatively, P＞0.05 illustrates that preparation of the present invention takes no overt toxicity for a long time, can guarantee the safety that human body is used.
For further verifying the therapeutic effect of preparation of the present invention, first Affiliated Hospital of Shanxi Medical College, Taiyuan City infectious hospital and three tame hospitals of Academy of Traditional Chinese Medicine, Shanxi Province Affiliated Hospital have carried out clinical verification to the therapeutic effect of preparation of the present invention jointly, and scientific evaluation has been made in its effectiveness and safety that prevents and treats the hepatitis disease.For this reason, three tame hospitals select 110 routine cases to carry out the clinical observation of system as observation group, and selected to distribute in sex distribution, age distribution, the course of disease, clinical symptoms distributes, clinical sign distributes, TCM Syndrome Type distributes, the sick 30 routine cases that all have a comparability with observation group of planting aspect eight of the relevant unusual person's distribution situations of biochemistry detection index that distributes etc. of doctor trained in Western medicine are organized in contrast and compared.Preparation of the present invention is taken by observation group, and each oral 10ml obeys three every day, and matched group is taken YIGANNING CHONGJI.12 weeks of observation period, during stop using the other treatment medicine.
The checking result contrasts confirmation, preparation of the present invention is for chronic hepatitis, chronic persistent hepatitis experimenter's clinical symptoms, the body card, the curative effect that lab index is improved obviously is better than contrasting medicine " YIGANNING CHONGJI ", wherein clinical symptoms improvement rate is learned to handle by statistics has the symptom of significant difference to have: feel sick, weak, poor appetite, abdominal distention, hypochondriac pain, waist soreness, feverish sensation in the palms and soles, dry mouth with bitter taste etc., what sign was improved the situation comparison there were significant differences has: jaundice, hepatosplenomegaly, the hepatic region tenderness, spider angioma, red tongue etc., lab index normalization rate have the AIT that has of significant difference, BIL.The checking result of TCM Syndrome Type confirm preparation of the present invention to move, the doing well,improving of the syndrome of deficiency of both qi and yin of chronic hepatitis B, deficiency of the yin of the liver card has significant curative effect, and is not obvious to the improvement of damp pathogen obstructing the spleen card.Behind the preparation for treating of the present invention among the HBV-M negative conversion rate of HBsAg be 17.27%, rate of descent is 48.18%, the negative conversion rate of HBeAg is 44.82%, anti-HBe sun rate of rotation is 39.34%, and matched group is respectively 3.33%, 33.33%, 30% and 40%, two groups of medicine contrast there was no significant differences, P＞0.05.
Preparation of the present invention is not found any side reaction in the clinical verification phase, therefore prove that said preparation has safety preferably.
During the final statistical result of clinical verification was listed in the table below, by following table as seen, two groups total effective rate contrast difference was remarkable, P＜0.01.
| Group | The example number | The basic routine number (%) of curing | Effective routine number (%) | Invalid routine number (%) | Total effective routine number (%) |
| Observation group | 110 | ?29(26.36) | 61(55.45) | 20(18.18) | 90(81.82) |
| Matched group | 30 | ?2(6.67) | 10(33.33) | 18(60) | 12(40) |
It below is several concrete Application Example of the present invention.
Embodiment 1: the exsiccant emerv formlcusius of selected 1000g, be ground into coarse powder with pulverizer, put into extractor, the water that adds 6L, room temperature flooded 24 hours down, leachate is filtered in the concentrator, add the water of 3L again in extractor, room temperature flooded 0.5 hour down, and leachate is also filtered in the concentrator, adopting decompression to steam the method that contracts concentrates leachate, until becoming the clear paste that relative density is 1.30-1.35 (55 ℃), clear paste taken out put into the precipitate with ethanol device and put coldly, it is complete to add dissolve with ethanol, make the alcohol amount that contains of solution reach 70%, staticly settled afterwards 24 hours, and the clear ripple of post precipitation is filtered in the distillator concentrated, and reclaim the ethanol that steams, until being concentrated into the Formica fusca concentrated solution that relative density is 1.30-1.35 (55 ℃), obtain 50mL approximately.
Get Radix Salviae Miltiorrhizae 1000g, Radix Astragali 500g, Rhizoma Polygonati 500g puts into extractor, the water that adds 6L, decocted 2 hours by classical decocting method, decocting liquid is filtered in the concentrator, residue adds the 6L decocting again and boiled 1.5 hours, decocting liquid is also filtered in the concentrator, adopt distillation under vacuum that decocting liquid is concentrated into the clear paste that relative density is 1.30-1.35 (55 ℃), take out and put into the precipitate with ethanol device and put coldly, it is complete to add dissolve with ethanol, make solution contain the alcohol amount and reach 70%, staticly settled afterwards 24 hours, and the post precipitation clear liquid is filtered in the distillator concentrated, and reclaim the ethanol that steams, until being concentrated into the Chinese medicine concentrated solution that relative density is 130-1.35 (55 ℃), obtain 100mL approximately.
50mL ant extract and 100mL Chinese medicine extraction liquid are merged, and thin up adds the 15g potassium sorbate to 10L, as antiseptic, stirs, and cold preservation is 48 hours under 0-4 ℃ of condition, filters, and obtains the oral liquid product after filtrate embedding, the sterilization.
Embodiment 2: merges ant extract clear paste and Chinese medicine extraction liquid clear paste among the embodiment 1, puts into spray drying tower, and the spray-dried granule of making, packing is made dissolved granule.
Embodiment 3: in granule incapsulates among the embodiment 2, make capsule.
Claims (11)
1, a kind of medicine for the treatment of hepatitis is characterized in that it is the medicament of being made by following materials based on weight: 20 parts of Formica fuscas, 20 parts of Radix Salviae Miltiorrhizaes, 10 parts of the Radixs Astragali, 10 parts of Rhizoma Polygonatis.
2, treatment hepatitis medicament according to claim 1 is characterized in that described Formica fusca is emerv formlcusius (Formica Sinae Emery).
3, treatment hepatitis medicament according to claim 1 and 2 is characterized in that made medicament is a said dosage form on any pharmaceutics.
4, treatment hepatitis medicament according to claim 3 is characterized in that described pharmaceutical formulation is an oral liquid.
5, the medicine of treatment hepatitis according to claim 3 is characterized in that described pharmaceutical formulation is dissolved granule or capsule.
6, the production method of the described treatment hepatitis medicament of claim 4 is characterized in that production method may further comprise the steps:
A 〉, Formica fusca powder is broken into coarse powder, adds water retting twice, floods 24 hours for the first time, floods 0.5 hour for the second time, with leachate simmer down to clear paste, adds ethanol and staticly settles 24 hours, gets supernatant concentration;
B 〉, Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Polygonati three flavor Chinese medicines decoct with water twice, 2 hours for the first time, 1.5 hours for the second time, decocting liquid simmer down to clear paste added ethanol and staticly settled 24 hours, gets supernatant concentration;
C 〉, merge two kinds of concentrated solutions, in 1: the ratio thin up of 5-8 is made oral liquid.
7, the production method of treatment hepatitis medicament according to claim 6 is characterized in that the described required water yield of water retting that adds, for the first time be dose 6-10 doubly, the second time be primary half.
8, the production method of treatment hepatitis medicament according to claim 6, it is characterized in that described decoct with water each required water yield be dose 6-10 doubly.
9, the production method of treatment hepatitis medicament according to claim 6 is characterized in that described concentrate is to be 1.30-1.35 (55 ℃) with liquid concentration to relative density.
10, the production method of treatment hepatitis medicament according to claim 6, it is characterized in that adding in the described ethanol precipitation alcoholic acid amount is to make the alcohol amount that contains of solution reach 70%.
11, the production method of treatment hepatitis medicament according to claim 6 is characterized in that also needing to make oral liquid in cooling 48 hours under the 0-4 ℃ of condition and after filtering behind the concentrated solution thin up.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99108167A CN1111064C (en) | 1999-06-10 | 1999-06-10 | Hepatitis treating medicine and its production process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99108167A CN1111064C (en) | 1999-06-10 | 1999-06-10 | Hepatitis treating medicine and its production process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1247755A true CN1247755A (en) | 2000-03-22 |
| CN1111064C CN1111064C (en) | 2003-06-11 |
Family
ID=5273176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99108167A Expired - Fee Related CN1111064C (en) | 1999-06-10 | 1999-06-10 | Hepatitis treating medicine and its production process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1111064C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100363045C (en) * | 2006-08-17 | 2008-01-23 | 江智文 | Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate for treating hepatitis accessorily |
| CN102872330A (en) * | 2012-10-11 | 2013-01-16 | 李天齐 | Chinese patent drug preparation for treating hepatitis |
| CN103977245A (en) * | 2014-04-18 | 2014-08-13 | 北京化工大学 | Drug for treating hepatitis B and preparation method thereof |
-
1999
- 1999-06-10 CN CN99108167A patent/CN1111064C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100363045C (en) * | 2006-08-17 | 2008-01-23 | 江智文 | Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate for treating hepatitis accessorily |
| CN102872330A (en) * | 2012-10-11 | 2013-01-16 | 李天齐 | Chinese patent drug preparation for treating hepatitis |
| CN103977245A (en) * | 2014-04-18 | 2014-08-13 | 北京化工大学 | Drug for treating hepatitis B and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1111064C (en) | 2003-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002213403A1 (en) | Novel medicinal herbal composition for treating liver diseases and HIV | |
| CN104623201B (en) | A kind of liver protection Elmination of toxicant and fat-lowering hypoglycemic medicine and its application | |
| CN102600423B (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN101049424A (en) | Medication for treating infection in respiratory system | |
| CN113679794A (en) | Uric acid-reducing sunflower disc composition and preparation method thereof | |
| CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN112915181A (en) | Qi-tonifying and vitality-restoring ointment formula and application thereof | |
| CN1111064C (en) | Hepatitis treating medicine and its production process | |
| CN100340286C (en) | Medicine for treating hepatitis B and its preparing method | |
| CN101186627A (en) | Method for preparing picroside I | |
| CN1233388C (en) | Combination of medicine for treating hepatitis | |
| CN1692938A (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN101574426B (en) | Chinese patent medicament for treating liver diseases and method for preparing same | |
| CN103830337B (en) | Chinese medicinal composition for treating chronic alcoholic toxic liver disease | |
| CN112826917A (en) | Compound mulberry and astragalus traditional Chinese medicine composition and application thereof | |
| CN101559166A (en) | Ophiopogon japonicus extract, preparation method and hypoglycemic application thereof | |
| CN100569247C (en) | A kind ofly set upright the liver benefiting Chinese medicine composition and preparation and application | |
| CN100386087C (en) | Use of kutkin I in preparing drug for treating hepatitis B, its formulation and preparation method | |
| CN1060051C (en) | Anti-cancer compn. and prepn. thereof | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN108721572B (en) | A Chinese medicinal composition for treating hepatocarcinoma and liver cirrhosis | |
| CN1569085A (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1242768C (en) | Hepatitis treating medicine and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |